Compare TPB & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPB | AAPG |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | United States | China |
| Employees | N/A | 767 |
| Industry | Tobacco | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2015 | N/A |
| Metric | TPB | AAPG |
|---|---|---|
| Price | $89.93 | $20.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $115.00 | $48.40 |
| AVG Volume (30 Days) | ★ 409.8K | 5.1K |
| Earning Date | 05-07-2026 | 05-20-2026 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | ★ 45.33 | N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $463,062,000.00 | N/A |
| Revenue This Year | $13.68 | $290.34 |
| Revenue Next Year | $11.32 | N/A |
| P/E Ratio | $28.72 | ★ N/A |
| Revenue Growth | ★ 28.39 | N/A |
| 52 Week Low | $65.80 | $18.56 |
| 52 Week High | $146.90 | $48.45 |
| Indicator | TPB | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 55.28 | 40.62 |
| Support Level | $83.01 | $20.11 |
| Resistance Level | $93.44 | $25.23 |
| Average True Range (ATR) | 4.50 | 0.79 |
| MACD | 0.29 | 0.05 |
| Stochastic Oscillator | 49.72 | 38.98 |
Turning Point Brands Inc operates as a manufacturer, marketer, and provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum, including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in two segments, namely Zig-Zag products and Stoker's products segment. The company generates maximum revenue from the Zig-Zag products segment.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.